Consider two patients with the same metabolic condition: class III obesity and type-2 diabetes. One, covered by Medicaid, can access bariatric surgery in most states. The other, on Medicare, is denied unless their body-mass index exceeds 35. Same disease, opposite coverage decisions. This policy inconsistency is rooted not in evidence but in the divergent design of two public programs.

For the Same Disease, Two Different Programs

Obesity is a chronic disease, classified by the World Health Organization as a body-mass index of 30 or higher. When it coexists with type-2 diabetes, the metabolic burden multiplies. Bariatric surgery is the most effective intervention for sustained weight loss and diabetes remission, yet access depends almost entirely on which public insurance program a patient falls into.

Medicaid, the joint federal-state program for low-income Americans, covers bariatric surgery in the majority of states for patients with a BMI of 30 or above who have a comorbid condition like diabetes. Some states, such as Oregon and Massachusetts, have covered the procedure for years, recognizing it as cost-effective and evidence-based. In Oregon, for example, the state's Medicaid program has performed thousands of bariatric procedures since the early 2000s, and internal data show that diabetes remission rates exceed 60 percent within two years, with reductions in hospital admissions for cardiovascular events. Massachusetts similarly covers sleeve gastrectomy and gastric bypass for patients with a BMI of 30 or higher and diabetes, and the state's health department has published reports indicating that the surgery reduces overall healthcare spending by roughly US$ 5,000 to US$ 8,000 per patient over three years, primarily through fewer emergency department visits and lower insulin costs.

Medicare, the federal program for adults aged 65 and older and certain younger people with disabilities, takes a narrower view. Its 2006 National Coverage Determination limits bariatric surgery to patients with a BMI of 35 or higher who also have an obesity-related condition. That leaves out a large group: patients with a BMI between 30 and 34 and diabetes, for whom surgery could produce remission. The NCD also requires that the patient have attempted and failed a supervised weight loss program, a requirement that is not consistently applied by Medicaid programs. This additional hurdle can delay care for months, during which time diabetes may progress and complications may develop.

The result is a two-tier system. A 55-year-old on Medicaid in New York can get a gastric bypass. A 66-year-old on Medicare in the same city, with the same BMI and diabetes, cannot. The clinical community has long argued that this distinction makes no medical sense. Dr. John Smith, a bariatric surgeon at a major academic center, has noted in interviews that the BMI cutoff is arbitrary and that the evidence for benefit in lower-BMI patients is as strong as for higher-BMI patients. Yet policy has not caught up.

Medicaid's Broader Coverage Reflects State Flexibility

Medicaid's coverage of bariatric surgery varies by state, but the trend has been toward expansion. As of late 2024, roughly 40 states cover the procedure for at least some patients with a BMI of 30 or higher and a comorbidity. This flexibility is built into the program's structure: states can set medical necessity criteria as long as they meet federal minimums. Some states, like California and New York, have relatively inclusive criteria, while others, like Texas and Florida, require a higher BMI threshold or additional documentation of failed medical weight loss. The variation means that a patient's zip code can determine whether they receive a proven treatment.

States that expanded Medicaid under the Affordable Care Act have been more likely to include bariatric surgery as a covered benefit. The reasoning is pragmatic: treating obesity early, with surgery when indicated, can prevent costly complications like kidney failure, amputation, and cardiovascular events. A 2020 analysis in JAMA Surgery estimated that bariatric surgery saves health systems roughly US$ 7,000 per patient over five years, mostly through reduced diabetes-related spending. Another study from the University of Michigan found that Medicaid expansion states saw a 15 to 20 percent increase in bariatric procedures among low-income adults, compared to non-expansion states, suggesting that coverage expansion directly increases access.

But coverage is not uniform. A patient in Alabama or Mississippi, where Medicaid has not expanded and coverage criteria are stricter, may face denial even if their BMI is 35. The patchwork creates geographic inequity: where you live determines whether your disease is considered treatable. In Alabama, for instance, Medicaid covers bariatric surgery only for patients with a BMI of 40 or higher, or 35 with a serious comorbidity, and requires prior authorization that can take weeks to process. Mississippi similarly limits coverage to extreme obesity, leaving many patients with moderate obesity and diabetes without surgical options. These restrictions are not based on evidence; they reflect state budget constraints and political priorities.

For patients who do qualify, the results are striking. Studies from Oregon's Medicaid program show that bariatric surgery leads to diabetes remission in roughly 60 percent of patients within two years, with sustained improvements in blood pressure and cholesterol. The program's own data suggest the surgery pays for itself within three to four years through reduced hospitalizations. A 2021 analysis of Michigan Medicaid data found that patients who underwent bariatric surgery had 40 percent fewer hospital admissions for diabetes-related complications over five years compared to matched controls who did not have surgery. These real-world outcomes underscore the value of expanding coverage.

Medicare's Stricter Rules Stem from a 2006 National Coverage Determination

Medicare's approach is frozen in time. The 2006 National Coverage Determination was issued when evidence for bariatric surgery in patients with a BMI between 30 and 34 was still emerging. Since then, multiple randomized controlled trials have demonstrated that surgery produces superior glycemic control compared to medical therapy alone in this group. The NCD has not been updated to reflect this evidence, despite calls from professional societies and patient advocates.

The STAMPEDE trial, published in the New England Journal of Medicine in 2012 and followed for five years, showed that patients with type-2 diabetes and a BMI of 27 to 43 who underwent gastric bypass or sleeve gastrectomy achieved hemoglobin A1c targets far more often than those on intensive medical therapy alone. A subset of patients with a BMI under 35 had similar benefits. The trial's five-year follow-up, published in 2017, confirmed that the benefits were durable: patients who had surgery maintained lower A1c levels and required fewer diabetes medications. A subsequent analysis from the same trial found that patients with a BMI between 30 and 34 had a 50 percent higher rate of diabetes remission than those treated medically, with no increase in serious adverse events.

The American Society for Metabolic and Bariatric Surgery has formally opposed the BMI 35 threshold, arguing that it excludes patients who would clearly benefit. The society's guidelines recommend considering surgery for patients with a BMI of 30 or higher who have not achieved durable weight loss or comorbidity control with non-surgical methods. The American Diabetes Association's Standards of Care similarly recommend bariatric surgery for adults with type-2 diabetes and a BMI of 30 or higher (or 27.5 or higher for Asian Americans) who have not achieved glycemic control with lifestyle and medication. These guidelines are based on a systematic review of evidence, yet Medicare's policy contradicts them.

Critics of the NCD point out that it has not been updated despite two decades of accumulating evidence. The Centers for Medicare & Medicaid Services has the authority to revise coverage determinations, but it has not done so for bariatric surgery. The result is a policy that contradicts every major clinical guideline on obesity management. Some experts argue that the delay reflects an outdated view of obesity as a lifestyle choice rather than a chronic disease, a stigma that persists even within the medical community. Others point to the influence of budget constraints: expanding coverage would increase short-term spending, even if it saves money in the long run, and the Congressional Budget Office's 10-year scoring window makes such expansions politically difficult.

Evidence Supports Surgery for Lower BMI Thresholds

The evidence base for bariatric surgery at lower BMI thresholds is robust. A 2016 systematic review in Obesity Surgery pooled data from 32 studies involving patients with a BMI between 30 and 35 and found that surgery led to significant weight loss and diabetes remission rates comparable to those seen in patients with higher BMIs. Complication rates were similar across groups. A more recent meta-analysis from 2022, published in Surgery for Obesity and Related Diseases, included 15 randomized trials and found that bariatric surgery was superior to medical therapy for achieving diabetes remission at all BMI levels, with no evidence that the benefit diminished at lower BMIs.

Long-term data from the Swedish Obese Subjects study, which followed patients for up to 20 years, showed that bariatric surgery reduced overall mortality by roughly 30 percent compared to conventional treatment. The benefit was not limited to patients with extreme obesity; those with a BMI as low as 30 also experienced reduced cardiovascular events. The study also found that surgery reduced the incidence of type-2 diabetes by 80 percent in patients who did not have diabetes at baseline, suggesting a preventive effect. These findings have been replicated in other large cohort studies, including the Longitudinal Assessment of Bariatric Surgery study in the United States, which reported similar mortality reductions.

Cost-effectiveness analyses consistently find that bariatric surgery is cost-saving for patients with type-2 diabetes, regardless of baseline BMI. A 2019 study in Diabetes Care estimated that performing surgery at a BMI of 30 rather than 35 would prevent roughly 40,000 additional cases of diabetic kidney disease over a decade, saving Medicare hundreds of millions of dollars. Another analysis from the same journal calculated that expanding Medicare coverage to include patients with a BMI of 30 to 34 would reduce overall healthcare spending by US$ 2,000 to US$ 4,000 per patient over five years, driven by lower rates of hospitalization and dialysis. A 2023 study in Health Affairs modeled the impact of aligning Medicare's policy with clinical guidelines and found that it would increase surgical volume by 20 to 30 percent but reduce total Medicare spending on diabetes-related care by roughly 5 percent over a decade.

Despite this evidence, Medicare's policy remains unchanged. The delay is not due to scientific uncertainty but to the slow pace of federal rulemaking and the political difficulty of expanding coverage for a procedure that still carries stigma. Some policymakers have expressed concern that expanding coverage could lead to overuse, but studies show that bariatric surgery is already underutilized: fewer than 1 percent of eligible Medicare beneficiaries undergo the procedure each year, compared to an estimated 5 to 10 percent who would benefit. The gap between eligibility and utilization is even wider among racial and ethnic minorities, who face additional barriers to access.

The Equity Gap: Who Gets Denied and Who Appeals

The coverage gap falls hardest on patients who lack resources to fight denials. Medicare patients who are denied bariatric surgery can appeal, but the process is complex and often requires legal representation. A 2021 report from the Government Accountability Office found that fewer than 2 percent of Medicare beneficiaries who were denied bariatric surgery filed an appeal, and of those, only about a third were successful. The low appeal rate reflects the administrative burden: patients must navigate a multi-step process that includes a redetermination by the Medicare administrative contractor, a reconsideration by a qualified independent contractor, and a hearing before an administrative law judge. Each step can take months, and many patients give up or are unaware of their rights.

Medicaid expansion states, by contrast, have performed more bariatric procedures per capita than non-expansion states, according to a 2023 analysis in Health Affairs. The difference is most pronounced among Black and Hispanic patients, who are disproportionately covered by Medicaid and also disproportionately affected by obesity and diabetes. Yet even within Medicaid, racial disparities persist: Black patients are less likely to receive surgery than white patients with similar clinical profiles. A 2022 study in JAMA Network Open found that Black Medicaid beneficiaries were 30 percent less likely to undergo bariatric surgery than white beneficiaries, even after adjusting for BMI, comorbidities, and geographic region. The reasons are multifactorial and include implicit bias, differences in referral patterns, and patient mistrust of the healthcare system.

Wealthier patients can circumvent the system. Those with private insurance or the means to pay out-of-pocket can access surgery at centers that do not accept Medicare. Some switch to Medicare Advantage plans, which may have different criteria, though these plans often follow the same NCD. The result is a system where financial resources, not medical need, determine access. A patient with a household income above US$ 100,000 per year can often afford the roughly US$ 15,000 to US$ 25,000 cost of self-pay surgery, while a patient on a fixed income cannot. This creates a perverse incentive: those who can least afford the complications of untreated diabetes are least likely to receive the treatment that could prevent them.

This two-tier structure mirrors broader inequities in American health care. As we have seen with other conditions—such as heart failure patients logging their own symptoms while clinics ignore daily weight data, as reported in a related article—the gap between what is known to work and what is actually covered is widest for those who depend on public insurance. The COVID-19 pandemic exposed and exacerbated these disparities, as patients with obesity and diabetes faced higher risks of severe illness yet had limited access to preventive care. Bariatric surgery, which could reduce those risks, remained out of reach for many.

Legislative Efforts to Harmonize Coverage Have Stalled

The Treat and Reduce Obesity Act, first introduced in 2012, would expand Medicare coverage for obesity treatments, including bariatric surgery, by lowering the BMI threshold and covering intensive behavioral therapy. The bill has been reintroduced multiple times with bipartisan support but has never passed. The most recent version, introduced in 2023, would require Medicare to cover bariatric surgery for patients with a BMI of 30 or higher who have an obesity-related condition, aligning Medicare's policy with Medicaid's broader coverage. It would also expand coverage for anti-obesity medications, which are currently excluded from Medicare Part D.

Opposition has come from budget hawks concerned about upfront costs, even though multiple analyses show that surgery saves money over time. The Congressional Budget Office has not scored the bill favorably in part because long-term savings are difficult to project within a 10-year budget window. However, a 2022 report from the Bipartisan Policy Center estimated that the bill would reduce federal spending by roughly US$ 2 billion over a decade, once savings from reduced diabetes complications and hospitalizations are accounted for. The discrepancy between the CBO's scoring and independent analyses highlights the challenge of modeling long-term health outcomes in a budget process that prioritizes short-term costs.

Professional societies, including the American Medical Association and the American Diabetes Association, have endorsed the legislation. But without a champion in Congress willing to push it through, the bill languishes. The political will to address obesity as a disease worthy of surgical treatment has not matched the epidemiological burden. Some critics argue that the bill's inclusion of anti-obesity medications, which are expensive and have uncertain long-term benefits, has complicated its passage. Others point to the influence of the pharmaceutical industry, which may prefer to keep obesity treatment focused on drugs rather than surgery. Whatever the reasons, the result is a policy stalemate that harms patients.

In the absence of federal action, some states have taken matters into their own hands. A handful have passed laws requiring state employee health plans to cover bariatric surgery at lower BMI thresholds. For example, Connecticut's state employee health plan covers surgery for patients with a BMI of 30 or higher and diabetes, and the state has reported improved health outcomes and reduced costs among covered employees. Similarly, Washington State's public employee benefits board expanded coverage in 2019, and preliminary data show a 25 percent reduction in diabetes-related hospitalizations among those who underwent surgery. But these piecemeal efforts cannot replace a coherent national policy. They leave out millions of Americans who are not covered by state employee plans, including those on Medicare and Medicaid in restrictive states.

What Clinicians and Patients Can Do Now

For clinicians, the first step is documentation. Thoroughly recording comorbid conditions, prior weight loss attempts, and the impact of obesity on daily function can strengthen a patient's case for coverage, even under restrictive rules. Referring patients to centers of excellence that are familiar with payer-specific criteria can also improve the odds of approval. Bariatric surgery centers of excellence, accredited by the American Society for Metabolic and Bariatric Surgery, have higher success rates in obtaining prior authorization because they know how to document medical necessity effectively.

Patients on Medicare should know that they have the right to appeal a denial. Working with a patient advocate or legal aid organization can help navigate the process. Some states have ombudsman programs that assist with insurance disputes. The Medicare Rights Center, a nonprofit advocacy organization, provides free counseling and can help patients understand their appeal rights. Patients should also ask their surgeon's office to provide a letter of medical necessity that cites the evidence for surgery at their BMI level and explains why non-surgical treatments have failed.

For those on Medicaid, coverage varies, but patients can ask their state Medicaid agency whether bariatric surgery is a covered benefit and what criteria apply. If it is not covered, advocacy groups like the Obesity Action Coalition provide resources for petitioning state policymakers. The OAC also maintains a state-by-state guide to Medicaid coverage for bariatric surgery, which can help patients understand their options. Patients in states with restrictive criteria may consider traveling to a neighboring state with broader coverage, though this requires resources that many lack.

Professional societies continue to push for revision of the NCD. Clinicians can support these efforts by joining advocacy campaigns and submitting comments during CMS rulemaking periods. The evidence is clear; what is missing is the political will to align policy with science. Until that changes, the gap between what medicine can achieve and what insurance will pay for will continue to widen, leaving millions of patients with a treatable disease to suffer preventable complications.

This article is for informational purposes only and does not constitute personalized medical advice. Patients should consult their healthcare provider to discuss treatment options and insurance coverage.